drksid,version_number,total_versions,version_date,recruitment_status,start_date,closing_date,enrolment,enrolment_type,min_age,max_age,gender,inclusion_criteria,exclusion_criteria,primary_outcomes,secondary_outcomes,contacts
DRKS00005594,1,10,2014-01-16,Recruiting planned,2014-02-15,NA,52,Planned,18 Years,70 Years,"Both, male and female","[""Additional Inclusion Criteria"",""1. Age: 18 - 70 years, both gender\n2. Patients with generalized chronic pruritus (being actively present for at least 6 weeks prior to screening) AND showing prurigo nodularis of dermatological, systemic or mixed origin\n3. Pruritus was refractory* to a four-week systemic antihistamine therapy (by history, any antihistamine; *no reduction of pruritus by more than two points on VAS)\n4. VAS ≥ 7 (in average during one of the past two days) at Baseline\n5. Signed informed consent\n6. Male patients agree to use a reliable method of birth control during the study.\n7. If the subject is a female of childbearing potential who:\n- has been strictly abstinent 1 month prior to baseline (V2) and agrees to continue for the duration of the clinical trial and for 2 months after end of study\n- and/or agrees to use a highly effective and approved contraceptive method(s) for the duration of the study and for 2 months after end of the study.\nA highly effective method of contraception is defined as:\no combined oral contraceptives (estrogens and progesterone) or implanted or in-jectable contraceptives with a stable dose for at least 1 month prior to Baseline visit AND use of preservative or\no bilateral tubal ligation\no or hormonal intra-uterine device (IUD) inserted at least 1 month prior to Base-line visit AND use of preservative\no or vasectomized partner for at least 3 months prior to baseline\nOr\nFemale of non-childbearing potential, defined as post menopausal (absence of menstrual bleeding for one year without any other medical reasons), hysterectomy or bilateral oophorectomy at Screening and Baseline visit""]","[""Exclusion Criteria"",""1. Patients with\na. chronic pruritus of paraneoplastic, neurogenic, and psychogenic origin\nb. pruritus of dermatologic origin with severe skin inflammation necessitating systemic anti-inflammatory therapy, for example urticaria, bullous pemphigoid, acute generalized flaring up in atopic dermatitis.\nc. localized pruritus (only a single area involved)\n2. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction and/or disease unless currently controlled and stable\n3. Subjects with an underlying known disease, a surgical or medical condition, which in the judgement of the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study or might confound the study assessments (e.g. other dermatological diseases), or might interfere with the subject’s study participation (e.g. planned hospitalization during the study) at Screening and Baseline visits\n4. Subjects with clinically significant abnormal laboratory values according to the Investigator at Screening visit\n5. Current psychosomatic and psychiatric diseases\n6. Current malignant disease and chemotherapy (e.g., hodgkins lymphoma during therapy)\n7. Chemotherapy with etoposide, vinorelbine\n8. Current and past use of topical (washout period 2 weeks) or systemic steroids (washout period 4 weeks) before baseline\n9. Current and past use before baseline of topical and systemic antihistamines such as cetirizine or loratadine (washout period 2 weeks) [remark: During the study the intake of cetirizine as rescue medication is allowed.]\n10. Current and past use before baseline of the following systemic drugs (washout period 4 weeks): cyclosporin A and other immunosuppressants, antiepileptics (e.g., midazolam) and anti-cholinergics, antidepressants, pain modulators (gabapentin/pregabalin), opioid receptor agonists or antagonists, anti-anxiety drugs, tranquilizers, hypnotics, antipsychotic drugs (e.g., pimozide)\n11. Current and past use before baseline and planned intake during the study of the following drugs (washout period 4 weeks):\n- drugs strongly inducing CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort (Hypericum perforatum, “Johanniskraut”),\n- ketoconazole, itraconazole, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon, protease inhibitors, irinotecan\n- pimozid, terfenadine, astemizole, cisapride\n- tacrolimus, sirolimus, everolimus, alfentanil, dihydroergotamin, ergotamin, fentanyl, chinidin\n- warfarin, midazolam, alprazolam, triazolam, acenocoumarol, tolbutamide\n12. Pregnancy, breast feeding\n13. Subjects currently enrolled in another investigational drug or device study or participated in such a study in the month prior to Baseline visit.\n14. Known hypersensitivity to aprepitant or to any of the excipients, especially sucrose (e.g. patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).""]","[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]","[""- intra-individual difference in verbal rating scale (VRS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively\n- intra-individual difference in VAS at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively.\n- Time course changes in VAS, VRS\n- Time course changes in DLQI and HADS\n- PBI-P index at visits 4 and 5, and at visits 7 and 8, respectively, compared to Baseline visit 2\n\n""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Münster"",""telephone"":""[---]*"",""fax"":""[---]*"",""email"":""[---]*"",""url"":""http://www.klinikum.uni-muenster.de"",""name"":""""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Kompetenzzentrum chronischer Pruritus (KCP) und Klinik für Hautkrankheiten Universitätsklinikum Münster"",""telephone"":""0251-8356534"",""fax"":""0251-8352559"",""email"":""sonja.staender at uni-muenster.de"",""url"":""[---]*"",""name"":""Ms. Prof. Dr. Sonja Ständer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsklinikum MünsterKlinik für HautkrankheitenZentrale Studienkoordination für innovative Dermatologie (ZiD)"",""telephone"":""0251-8356558"",""fax"":""[---]*"",""email"":""Athanasios.Tsianakas at ukmuenster.de"",""url"":""[---]*"",""name"":""Mr. Dr. Athanasios Tsianakas""}]"
DRKS00005594,2,10,2014-01-21,Recruiting planned,2014-02-15,NA,52,Planned,18 Years,70 Years,"Both, male and female","[""Additional Inclusion Criteria"",""1. Age: 18 - 70 years, both gender\n2. Patients with generalized chronic pruritus (being actively present for at least 6 weeks prior to screening) AND showing prurigo nodularis of dermatological, systemic or mixed origin\n3. Pruritus was refractory* to a four-week systemic antihistamine therapy (by history, any antihistamine; *no reduction of pruritus by more than two points on VAS)\n4. VAS ≥ 7 (in average during one of the past two days) at Baseline\n5. Signed informed consent\n6. Male patients agree to use a reliable method of birth control during the study.\n7. If the subject is a female of childbearing potential who:\n- has been strictly abstinent 1 month prior to baseline (V2) and agrees to continue for the duration of the clinical trial and for 2 months after end of study\n- and/or agrees to use a highly effective and approved contraceptive method(s) for the duration of the study and for 2 months after end of the study.\nA highly effective method of contraception is defined as:\no combined oral contraceptives (estrogens and progesterone) or implanted or in-jectable contraceptives with a stable dose for at least 1 month prior to Baseline visit AND use of preservative or\no bilateral tubal ligation\no or hormonal intra-uterine device (IUD) inserted at least 1 month prior to Base-line visit AND use of preservative\no or vasectomized partner for at least 3 months prior to baseline\nOr\nFemale of non-childbearing potential, defined as post menopausal (absence of menstrual bleeding for one year without any other medical reasons), hysterectomy or bilateral oophorectomy at Screening and Baseline visit""]","[""Exclusion Criteria"",""1. Patients with\na. chronic pruritus of paraneoplastic, neurogenic, and psychogenic origin\nb. pruritus of dermatologic origin with severe skin inflammation necessitating systemic anti-inflammatory therapy, for example urticaria, bullous pemphigoid, acute generalized flaring up in atopic dermatitis.\nc. localized pruritus (only a single area involved)\n2. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction and/or disease unless currently controlled and stable\n3. Subjects with an underlying known disease, a surgical or medical condition, which in the judgement of the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study or might confound the study assessments (e.g. other dermatological diseases), or might interfere with the subject’s study participation (e.g. planned hospitalization during the study) at Screening and Baseline visits\n4. Subjects with clinically significant abnormal laboratory values according to the Investigator at Screening visit\n5. Current psychosomatic and psychiatric diseases\n6. Current malignant disease and chemotherapy (e.g., hodgkins lymphoma during therapy)\n7. Chemotherapy with etoposide, vinorelbine\n8. Current and past use of topical (washout period 2 weeks) or systemic steroids (washout period 4 weeks) before baseline\n9. Current and past use before baseline of topical and systemic antihistamines such as cetirizine or loratadine (washout period 2 weeks) [remark: During the study the intake of cetirizine as rescue medication is allowed.]\n10. Current and past use before baseline of the following systemic drugs (washout period 4 weeks): cyclosporin A and other immunosuppressants, antiepileptics (e.g., midazolam) and anti-cholinergics, antidepressants, pain modulators (gabapentin/pregabalin), opioid receptor agonists or antagonists, anti-anxiety drugs, tranquilizers, hypnotics, antipsychotic drugs (e.g., pimozide)\n11. Current and past use before baseline and planned intake during the study of the following drugs (washout period 4 weeks):\n- drugs strongly inducing CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort (Hypericum perforatum, “Johanniskraut”),\n- ketoconazole, itraconazole, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon, protease inhibitors, irinotecan\n- pimozid, terfenadine, astemizole, cisapride\n- tacrolimus, sirolimus, everolimus, alfentanil, dihydroergotamin, ergotamin, fentanyl, chinidin\n- warfarin, midazolam, alprazolam, triazolam, acenocoumarol, tolbutamide\n12. Pregnancy, breast feeding\n13. Subjects currently enrolled in another investigational drug or device study or participated in such a study in the month prior to Baseline visit.\n14. Known hypersensitivity to aprepitant or to any of the excipients, especially sucrose (e.g. patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).""]","[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]","[""- intra-individual difference in verbal rating scale (VRS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively\n- intra-individual difference in VAS at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively.\n- Time course changes in VAS, VRS\n- Time course changes in DLQI and HADS\n- PBI-P index at visits 4 and 5, and at visits 7 and 8, respectively, compared to Baseline visit 2\n\n""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Münster"",""telephone"":""[---]*"",""fax"":""[---]*"",""email"":""[---]*"",""url"":""http://www.klinikum.uni-muenster.de"",""name"":""""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Kompetenzzentrum chronischer Pruritus (KCP) und Klinik für Hautkrankheiten Universitätsklinikum Münster"",""telephone"":""0251-8356534"",""fax"":""0251-8352559"",""email"":""sonja.staender at uni-muenster.de"",""url"":""[---]*"",""name"":""Ms. Prof. Dr. Sonja Ständer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsklinikum MünsterKlinik für HautkrankheitenZentrale Studienkoordination für innovative Dermatologie (ZiD)"",""telephone"":""0251-8356558"",""fax"":""[---]*"",""email"":""Athanasios.Tsianakas at ukmuenster.de"",""url"":""[---]*"",""name"":""Mr. Dr. Athanasios Tsianakas""}]"
DRKS00005594,3,10,2014-07-23,Recruiting ongoing,2014-06-30,NA,52,Actual,18 Years,70 Years,"Both, male and female","[""Additional Inclusion Criteria"",""1. Age: 18 - 70 years, both gender\n2. Patients with generalized chronic pruritus (being actively present for at least 6 weeks prior to screening) AND showing prurigo nodularis of dermatological, systemic or mixed origin\n3. Pruritus was refractory* to a four-week systemic antihistamine therapy (by history, any antihistamine; *no reduction of pruritus by more than two points on VAS)\n4. VAS ≥ 7 (in average during one of the past two days) at Baseline\n5. Signed informed consent\n6. Male patients agree to use a reliable method of birth control during the study.\n7. If the subject is a female of childbearing potential who:\n- has been strictly abstinent 1 month prior to baseline (V2) and agrees to continue for the duration of the clinical trial and for 2 months after end of study\n- and/or agrees to use a highly effective and approved contraceptive method(s) for the duration of the study and for 2 months after end of the study.\nA highly effective method of contraception is defined as:\no combined oral contraceptives (estrogens and progesterone) or implanted or in-jectable contraceptives with a stable dose for at least 1 month prior to Baseline visit AND use of preservative or\no bilateral tubal ligation\no or hormonal intra-uterine device (IUD) inserted at least 1 month prior to Base-line visit AND use of preservative\no or vasectomized partner for at least 3 months prior to baseline\nOr\nFemale of non-childbearing potential, defined as post menopausal (absence of menstrual bleeding for one year without any other medical reasons), hysterectomy or bilateral oophorectomy at Screening and Baseline visit""]","[""Exclusion Criteria"",""1. Patients with\na. chronic pruritus of paraneoplastic, neurogenic, and psychogenic origin\nb. pruritus of dermatologic origin with severe skin inflammation necessitating systemic anti-inflammatory therapy, for example urticaria, bullous pemphigoid, acute generalized flaring up in atopic dermatitis.\nc. localized pruritus (only a single area involved)\n2. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction and/or disease unless currently controlled and stable\n3. Subjects with an underlying known disease, a surgical or medical condition, which in the judgement of the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study or might confound the study assessments (e.g. other dermatological diseases), or might interfere with the subject’s study participation (e.g. planned hospitalization during the study) at Screening and Baseline visits\n4. Subjects with clinically significant abnormal laboratory values according to the Investigator at Screening visit\n5. Current psychosomatic and psychiatric diseases\n6. Current malignant disease and chemotherapy (e.g., hodgkins lymphoma during therapy)\n7. Chemotherapy with etoposide, vinorelbine\n8. Current and past use of topical (washout period 2 weeks) or systemic steroids (washout period 4 weeks) before baseline\n9. Current and past use before baseline of topical and systemic antihistamines such as cetirizine or loratadine (washout period 2 weeks) [remark: During the study the intake of cetirizine as rescue medication is allowed.]\n10. Current and past use before baseline of the following systemic drugs (washout period 4 weeks): ultraviolet A or B light therapy, cyclosporin A and other immunosuppressants, antiepileptics (e.g., midazolam) and anti-cholinergics, antidepressants, pain modulators (gabapentin/pregabalin), opioid receptor agonists or antagonists, anti-anxiety drugs, tranquilizers, hypnotics, antipsychotic drugs (e.g., pimozide)\n11. Current and past use before baseline and planned intake during the study of the following drugs (washout period 4 weeks):\n- drugs strongly inducing CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort (Hypericum perforatum, “Johanniskraut”),\n- ketoconazole, itraconazole, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon, protease inhibitors, irinotecan\n- pimozid, terfenadine, astemizole, cisapride\n- tacrolimus, sirolimus, everolimus, alfentanil, dihydroergotamin, ergotamin, fentanyl, chinidin\n- warfarin, phenprcoumon, midazolam, alprazolam, triazolam, acenocoumarol, tolbutamide\n12. Pregnancy, breast feeding\n13. Subjects currently enrolled in another investigational drug or device study or participated in such a study in the month prior to Baseline visit.\n14. Known hypersensitivity to aprepitant or to any of the excipients, especially sucrose (e.g. patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).""]","[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]","[""- intra-individual difference in verbal rating scale (VRS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively\n- intra-individual difference in VAS at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively.\n- Time course changes in VAS, VRS\n- Time course changes in DLQI, HADS and ItchyQol\n- PBI-P index at visits 4 and 5, and at visits 7 and 8, respectively, compared to Baseline visit 2\n\n""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Münster"",""telephone"":""[---]*"",""fax"":""[---]*"",""email"":""[---]*"",""url"":""http://www.klinikum.uni-muenster.de"",""name"":""""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Kompetenzzentrum chronischer Pruritus (KCP) und Klinik für Hautkrankheiten Universitätsklinikum Münster"",""telephone"":""0251-8356534"",""fax"":""0251-8352559"",""email"":""sonja.staender at uni-muenster.de"",""url"":""[---]*"",""name"":""Ms. Prof. Dr. Sonja Ständer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsklinikum MünsterKlinik für HautkrankheitenZentrale Studienkoordination für innovative Dermatologie (ZiD)"",""telephone"":""0251-8356558"",""fax"":""[---]*"",""email"":""Athanasios.Tsianakas at ukmuenster.de"",""url"":""[---]*"",""name"":""Mr. Dr. Athanasios Tsianakas""}]"
DRKS00005594,4,10,2015-01-20,Recruiting ongoing,2014-06-30,NA,52,Actual,18 Years,70 Years,"Both, male and female","[""Additional Inclusion Criteria"",""1. Age: 18 - 70 years, both gender\n2. Patients with generalized chronic pruritus (being actively present for at least 6 weeks prior to screening) AND showing prurigo nodularis of dermatological, systemic or mixed origin\n3. Pruritus was refractory* to a four-week systemic antihistamine therapy (by history, any antihistamine; *no reduction of pruritus by more than two points on VAS)\n4. VAS ≥ 7 (in average during one of the past two days) at Baseline\n5. Signed informed consent\n6. Male patients agree to use a reliable method of birth control during the study.\n7. If the subject is a female of childbearing potential who:\n- has been strictly abstinent 1 month prior to baseline (V2) and agrees to continue for the duration of the clinical trial and for 2 months after end of study\n- and/or agrees to use a highly effective and approved contraceptive method(s) for the duration of the study and for 2 months after end of the study.\nA highly effective method of contraception is defined as:\no combined oral contraceptives (estrogens and progesterone) or implanted or in-jectable contraceptives with a stable dose for at least 1 month prior to Baseline visit AND use of preservative or\no bilateral tubal ligation\no or hormonal intra-uterine device (IUD) inserted at least 1 month prior to Base-line visit AND use of preservative\no or vasectomized partner for at least 3 months prior to baseline\nOr\nFemale of non-childbearing potential, defined as post menopausal (absence of menstrual bleeding for one year without any other medical reasons), hysterectomy or bilateral oophorectomy at Screening and Baseline visit""]","[""Exclusion Criteria"",""1. Patients with\na. chronic pruritus of paraneoplastic, neurogenic, and psychogenic origin\nb. pruritus of dermatologic origin with severe skin inflammation necessitating systemic anti-inflammatory therapy, for example urticaria, bullous pemphigoid, acute generalized flaring up in atopic dermatitis.\nc. localized pruritus (only a single area involved)\n2. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction and/or disease unless currently controlled and stable\n3. Subjects with an underlying known disease, a surgical or medical condition, which in the judgement of the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study or might confound the study assessments (e.g. other dermatological diseases), or might interfere with the subject’s study participation (e.g. planned hospitalization during the study) at Screening and Baseline visits\n4. Subjects with clinically significant abnormal laboratory values according to the Investigator at Screening visit\n5. Current psychosomatic and psychiatric diseases\n6. Current malignant disease and chemotherapy (e.g., hodgkins lymphoma during therapy)\n7. Chemotherapy with etoposide, vinorelbine\n8. Current and past use of topical (washout period 2 weeks) or systemic steroids (washout period 4 weeks) before baseline\n9. Current and past use before baseline of topical and systemic antihistamines such as cetirizine or loratadine (washout period 2 weeks) [remark: During the study the intake of cetirizine as rescue medication is allowed.]\n10. Current and past use before baseline of the following systemic drugs (washout period 4 weeks): ultraviolet A or B light therapy, cyclosporin A and other immunosuppressants, antiepileptics (e.g., midazolam) and anti-cholinergics, antidepressants, pain modulators (gabapentin/pregabalin), opioid receptor agonists or antagonists, anti-anxiety drugs, tranquilizers, hypnotics, antipsychotic drugs (e.g., pimozide)\n11. Current and past use before baseline and planned intake during the study of the following drugs (washout period 4 weeks):\n- drugs strongly inducing CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort (Hypericum perforatum, “Johanniskraut”),\n- ketoconazole, itraconazole, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon, protease inhibitors, irinotecan\n- pimozid, terfenadine, astemizole, cisapride\n- tacrolimus, sirolimus, everolimus, alfentanil, dihydroergotamin, ergotamin, fentanyl, chinidin\n- warfarin, phenprcoumon, midazolam, alprazolam, triazolam, acenocoumarol, tolbutamide\n12. Pregnancy, breast feeding\n13. Subjects currently enrolled in another investigational drug or device study or participated in such a study in the month prior to Baseline visit.\n14. Known hypersensitivity to aprepitant or to any of the excipients, especially sucrose (e.g. patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).""]","[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]","[""- intra-individual difference in verbal rating scale (VRS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively\n- intra-individual difference in VAS at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively.\n- Time course changes in VAS, VRS\n- Time course changes in DLQI, HADS and ItchyQol\n- PBI-P index at visits 4 and 5, and at visits 7 and 8, respectively, compared to Baseline visit 2\n\n""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Münster"",""telephone"":""[---]*"",""fax"":""[---]*"",""email"":""[---]*"",""url"":""http://www.klinikum.uni-muenster.de"",""name"":""""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Kompetenzzentrum chronischer Pruritus (KCP) und Klinik für Hautkrankheiten Universitätsklinikum Münster"",""telephone"":""0251-8356534"",""fax"":""0251-8352559"",""email"":""sonja.staender at uni-muenster.de"",""url"":""[---]*"",""name"":""Ms. Prof. Dr. Sonja Ständer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsklinikum MünsterKlinik für HautkrankheitenZentrale Studienkoordination für innovative Dermatologie (ZiD)"",""telephone"":""0251-8356558"",""fax"":""[---]*"",""email"":""Athanasios.Tsianakas at ukmuenster.de"",""url"":""[---]*"",""name"":""Mr. Dr. Athanasios Tsianakas""}]"
DRKS00005594,5,10,2015-07-22,Recruiting ongoing,2014-06-30,NA,56,Actual,18 Years,70 Years,"Both, male and female","[""Additional Inclusion Criteria"",""1. Age: 18 - 70 years, both gender\n2. Patients with generalized chronic pruritus (being actively present for at least 6 weeks prior to screening) AND showing prurigo nodularis of dermatological, systemic or mixed origin\n3. Pruritus was refractory* to a four-week systemic antihistamine therapy (by history, any antihistamine; *no reduction of pruritus by more than two points on VAS)\n4. VAS ≥ 7 (in average during one of the past two days) at Baseline\n5. Signed informed consent\n6. Male patients agree to use a reliable method of birth control during the study.\n7. If the subject is a female of childbearing potential who:\n- has been strictly abstinent 1 month prior to baseline (V2) and agrees to continue for the duration of the clinical trial and for 2 months after end of study\n- and/or agrees to use a highly effective and approved contraceptive method(s) for the duration of the study and for 2 months after end of the study.\nA highly effective method of contraception is defined as:\no combined oral contraceptives (estrogens and progesterone) or implanted or in-jectable contraceptives with a stable dose for at least 1 month prior to Baseline visit AND use of preservative or\no bilateral tubal ligation\no or hormonal intra-uterine device (IUD) inserted at least 1 month prior to Base-line visit AND use of preservative\no or vasectomized partner for at least 3 months prior to baseline\nOr\nFemale of non-childbearing potential, defined as post menopausal (absence of menstrual bleeding for one year without any other medical reasons), hysterectomy or bilateral oophorectomy at Screening and Baseline visit""]","[""Exclusion Criteria"",""1. Patients with\na. chronic pruritus of paraneoplastic, neurogenic, and psychogenic origin\nb. pruritus of dermatologic origin with severe skin inflammation necessitating systemic anti-inflammatory therapy, for example urticaria, bullous pemphigoid, acute generalized flaring up in atopic dermatitis.\nc. localized pruritus (only a single area involved)\n2. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction and/or disease unless currently controlled and stable\n3. Subjects with an underlying known disease, a surgical or medical condition, which in the judgement of the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study or might confound the study assessments (e.g. other dermatological diseases), or might interfere with the subject’s study participation (e.g. planned hospitalization during the study) at Screening and Baseline visits\n4. Subjects with clinically significant abnormal laboratory values according to the Investigator at Screening visit\n5. Current psychosomatic and psychiatric diseases\n6. Current malignant disease and chemotherapy (e.g., hodgkins lymphoma during therapy)\n7. Chemotherapy with etoposide, vinorelbine\n8. Current and past use of topical (washout period 2 weeks) or systemic steroids (washout period 4 weeks) before baseline\n9. Current and past use before baseline of topical and systemic antihistamines such as cetirizine or loratadine (washout period 2 weeks) [remark: During the study the intake of cetirizine as rescue medication is allowed.]\n10. Current and past use before baseline of the following systemic drugs (washout period 4 weeks): ultraviolet A or B light therapy, cyclosporin A and other immunosuppressants, antiepileptics (e.g., midazolam) and anti-cholinergics, antidepressants, pain modulators (gabapentin/pregabalin), opioid receptor agonists or antagonists, anti-anxiety drugs, tranquilizers, hypnotics, antipsychotic drugs (e.g., pimozide)\n11. Current and past use before baseline and planned intake during the study of the following drugs (washout period 4 weeks):\n- drugs strongly inducing CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort (Hypericum perforatum, “Johanniskraut”),\n- ketoconazole, itraconazole, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon, protease inhibitors, irinotecan\n- pimozid, terfenadine, astemizole, cisapride\n- tacrolimus, sirolimus, everolimus, alfentanil, dihydroergotamin, ergotamin, fentanyl, chinidin\n- warfarin, phenprcoumon, midazolam, alprazolam, triazolam, acenocoumarol, tolbutamide\n12. Pregnancy, breast feeding\n13. Subjects currently enrolled in another investigational drug or device study or participated in such a study in the month prior to Baseline visit.\n14. Known hypersensitivity to aprepitant or to any of the excipients, especially sucrose (e.g. patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).""]","[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]","[""- intra-individual difference in verbal rating scale (VRS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively\n- intra-individual difference in VAS at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively.\n- Time course changes in VAS, VRS\n- Time course changes in DLQI, HADS and ItchyQol\n- PBI-P index at visits 4 and 5, and at visits 7 and 8, respectively, compared to Baseline visit 2\n\n""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Münster"",""telephone"":""[---]*"",""fax"":""[---]*"",""email"":""[---]*"",""url"":""http://www.klinikum.uni-muenster.de"",""name"":""""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Kompetenzzentrum chronischer Pruritus (KCP) und Klinik für Hautkrankheiten Universitätsklinikum Münster"",""telephone"":""0251-8356534"",""fax"":""0251-8352559"",""email"":""sonja.staender at uni-muenster.de"",""url"":""[---]*"",""name"":""Ms. Prof. Dr. Sonja Ständer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsklinikum MünsterKlinik für HautkrankheitenZentrale Studienkoordination für innovative Dermatologie (ZiD)"",""telephone"":""0251-8356558"",""fax"":""[---]*"",""email"":""Athanasios.Tsianakas at ukmuenster.de"",""url"":""[---]*"",""name"":""Mr. Dr. Athanasios Tsianakas""}]"
DRKS00005594,6,10,2016-02-11,"Recruiting complete, follow-up complete",2014-06-30,2016-01-04,58,Actual,18 Years,70 Years,"Both, male and female","[""Additional Inclusion Criteria"",""1. Age: 18 - 70 years, both gender\n2. Patients with generalized chronic pruritus (being actively present for at least 6 weeks prior to screening) AND showing prurigo nodularis of dermatological, systemic or mixed origin\n3. Pruritus was refractory* to a four-week systemic antihistamine therapy (by history, any antihistamine; *no reduction of pruritus by more than two points on VAS)\n4. VAS ≥ 7 (in average during one of the past two days) at Baseline\n5. Signed informed consent\n6. Male patients agree to use a reliable method of birth control during the study.\n7. If the subject is a female of childbearing potential who:\n- has been strictly abstinent 1 month prior to baseline (V2) and agrees to continue for the duration of the clinical trial and for 2 months after end of study\n- and/or agrees to use a highly effective and approved contraceptive method(s) for the duration of the study and for 2 months after end of the study.\nA highly effective method of contraception is defined as:\no combined oral contraceptives (estrogens and progesterone) or implanted or in-jectable contraceptives with a stable dose for at least 1 month prior to Baseline visit AND use of preservative or\no bilateral tubal ligation\no or hormonal intra-uterine device (IUD) inserted at least 1 month prior to Base-line visit AND use of preservative\no or vasectomized partner for at least 3 months prior to baseline\nOr\nFemale of non-childbearing potential, defined as post menopausal (absence of menstrual bleeding for one year without any other medical reasons), hysterectomy or bilateral oophorectomy at Screening and Baseline visit""]","[""Exclusion Criteria"",""1. Patients with\na. chronic pruritus of paraneoplastic, neurogenic, and psychogenic origin\nb. pruritus of dermatologic origin with severe skin inflammation necessitating systemic anti-inflammatory therapy, for example urticaria, bullous pemphigoid, acute generalized flaring up in atopic dermatitis.\nc. localized pruritus (only a single area involved)\n2. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction and/or disease unless currently controlled and stable\n3. Subjects with an underlying known disease, a surgical or medical condition, which in the judgement of the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study or might confound the study assessments (e.g. other dermatological diseases), or might interfere with the subject’s study participation (e.g. planned hospitalization during the study) at Screening and Baseline visits\n4. Subjects with clinically significant abnormal laboratory values according to the Investigator at Screening visit\n5. Current psychosomatic and psychiatric diseases\n6. Current malignant disease and chemotherapy (e.g., hodgkins lymphoma during therapy)\n7. Chemotherapy with etoposide, vinorelbine\n8. Current and past use of topical (washout period 2 weeks) or systemic steroids (washout period 4 weeks) before baseline\n9. Current and past use before baseline of topical and systemic antihistamines such as cetirizine or loratadine (washout period 2 weeks) [remark: During the study the intake of cetirizine as rescue medication is allowed.]\n10. Current and past use before baseline of the following systemic drugs (washout period 4 weeks): ultraviolet A or B light therapy, cyclosporin A and other immunosuppressants, antiepileptics (e.g., midazolam) and anti-cholinergics, antidepressants, pain modulators (gabapentin/pregabalin), opioid receptor agonists or antagonists, anti-anxiety drugs, tranquilizers, hypnotics, antipsychotic drugs (e.g., pimozide)\n11. Current and past use before baseline and planned intake during the study of the following drugs (washout period 4 weeks):\n- drugs strongly inducing CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort (Hypericum perforatum, “Johanniskraut”),\n- ketoconazole, itraconazole, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon, protease inhibitors, irinotecan\n- pimozid, terfenadine, astemizole, cisapride\n- tacrolimus, sirolimus, everolimus, alfentanil, dihydroergotamin, ergotamin, fentanyl, chinidin\n- warfarin, phenprcoumon, midazolam, alprazolam, triazolam, acenocoumarol, tolbutamide\n12. Pregnancy, breast feeding\n13. Subjects currently enrolled in another investigational drug or device study or participated in such a study in the month prior to Baseline visit.\n14. Known hypersensitivity to aprepitant or to any of the excipients, especially sucrose (e.g. patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).""]","[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]","[""- intra-individual difference in verbal rating scale (VRS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively\n- intra-individual difference in VAS at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively.\n- Time course changes in VAS, VRS\n- Time course changes in DLQI, HADS and ItchyQol\n- PBI-P index at visits 4 and 5, and at visits 7 and 8, respectively, compared to Baseline visit 2\n\n""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Münster"",""telephone"":""[---]*"",""fax"":""[---]*"",""email"":""[---]*"",""url"":""http://www.klinikum.uni-muenster.de"",""name"":""""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Kompetenzzentrum chronischer Pruritus (KCP) und Klinik für Hautkrankheiten Universitätsklinikum Münster"",""telephone"":""0251-8356534"",""fax"":""0251-8352559"",""email"":""sonja.staender at uni-muenster.de"",""url"":""[---]*"",""name"":""Ms. Prof. Dr. Sonja Ständer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsklinikum MünsterKlinik für HautkrankheitenZentrale Studienkoordination für innovative Dermatologie (ZiD)"",""telephone"":""0251-8356558"",""fax"":""[---]*"",""email"":""Athanasios.Tsianakas at ukmuenster.de"",""url"":""[---]*"",""name"":""Mr. Dr. Athanasios Tsianakas""}]"
DRKS00005594,7,10,2016-08-15,"Recruiting complete, follow-up complete",2014-06-30,2016-01-04,58,Actual,18 Years,70 Years,"Both, male and female","[""Additional Inclusion Criteria"",""1. Age: 18 - 70 years, both gender\n2. Patients with generalized chronic pruritus (being actively present for at least 6 weeks prior to screening) AND showing prurigo nodularis of dermatological, systemic or mixed origin\n3. Pruritus was refractory* to a four-week systemic antihistamine therapy (by history, any antihistamine; *no reduction of pruritus by more than two points on VAS)\n4. VAS ≥ 7 (in average during one of the past two days) at Baseline\n5. Signed informed consent\n6. Male patients agree to use a reliable method of birth control during the study.\n7. If the subject is a female of childbearing potential who:\n- has been strictly abstinent 1 month prior to baseline (V2) and agrees to continue for the duration of the clinical trial and for 2 months after end of study\n- and/or agrees to use a highly effective and approved contraceptive method(s) for the duration of the study and for 2 months after end of the study.\nA highly effective method of contraception is defined as:\no combined oral contraceptives (estrogens and progesterone) or implanted or in-jectable contraceptives with a stable dose for at least 1 month prior to Baseline visit AND use of preservative or\no bilateral tubal ligation\no or hormonal intra-uterine device (IUD) inserted at least 1 month prior to Base-line visit AND use of preservative\no or vasectomized partner for at least 3 months prior to baseline\nOr\nFemale of non-childbearing potential, defined as post menopausal (absence of menstrual bleeding for one year without any other medical reasons), hysterectomy or bilateral oophorectomy at Screening and Baseline visit""]","[""Exclusion Criteria"",""1. Patients with\na. chronic pruritus of paraneoplastic, neurogenic, and psychogenic origin\nb. pruritus of dermatologic origin with severe skin inflammation necessitating systemic anti-inflammatory therapy, for example urticaria, bullous pemphigoid, acute generalized flaring up in atopic dermatitis.\nc. localized pruritus (only a single area involved)\n2. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction and/or disease unless currently controlled and stable\n3. Subjects with an underlying known disease, a surgical or medical condition, which in the judgement of the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study or might confound the study assessments (e.g. other dermatological diseases), or might interfere with the subject’s study participation (e.g. planned hospitalization during the study) at Screening and Baseline visits\n4. Subjects with clinically significant abnormal laboratory values according to the Investigator at Screening visit\n5. Current psychosomatic and psychiatric diseases\n6. Current malignant disease and chemotherapy (e.g., hodgkins lymphoma during therapy)\n7. Chemotherapy with etoposide, vinorelbine\n8. Current and past use of topical (washout period 2 weeks) or systemic steroids (washout period 4 weeks) before baseline\n9. Current and past use before baseline of topical and systemic antihistamines such as cetirizine or loratadine (washout period 2 weeks) [remark: During the study the intake of cetirizine as rescue medication is allowed.]\n10. Current and past use before baseline of the following systemic drugs (washout period 4 weeks): ultraviolet A or B light therapy, cyclosporin A and other immunosuppressants, antiepileptics (e.g., midazolam) and anti-cholinergics, antidepressants, pain modulators (gabapentin/pregabalin), opioid receptor agonists or antagonists, anti-anxiety drugs, tranquilizers, hypnotics, antipsychotic drugs (e.g., pimozide)\n11. Current and past use before baseline and planned intake during the study of the following drugs (washout period 4 weeks):\n- drugs strongly inducing CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort (Hypericum perforatum, “Johanniskraut”),\n- ketoconazole, itraconazole, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon, protease inhibitors, irinotecan\n- pimozid, terfenadine, astemizole, cisapride\n- tacrolimus, sirolimus, everolimus, alfentanil, dihydroergotamin, ergotamin, fentanyl, chinidin\n- warfarin, phenprcoumon, midazolam, alprazolam, triazolam, acenocoumarol, tolbutamide\n12. Pregnancy, breast feeding\n13. Subjects currently enrolled in another investigational drug or device study or participated in such a study in the month prior to Baseline visit.\n14. Known hypersensitivity to aprepitant or to any of the excipients, especially sucrose (e.g. patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).""]","[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]","[""- intra-individual difference in verbal rating scale (VRS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively\n- intra-individual difference in VAS at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively.\n- Time course changes in VAS, VRS\n- Time course changes in DLQI, HADS and ItchyQol\n- PBI-P index at visits 4 and 5, and at visits 7 and 8, respectively, compared to Baseline visit 2\n\n""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Münster"",""telephone"":""[---]*"",""fax"":""[---]*"",""email"":""[---]*"",""url"":""http://www.klinikum.uni-muenster.de"",""name"":""""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Kompetenzzentrum chronischer Pruritus (KCP) und Klinik für Hautkrankheiten Universitätsklinikum Münster"",""telephone"":""0251-8356534"",""fax"":""0251-8352559"",""email"":""sonja.staender at uni-muenster.de"",""url"":""[---]*"",""name"":""Ms. Prof. Dr. Sonja Ständer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsklinikum MünsterKlinik für HautkrankheitenZentrale Studienkoordination für innovative Dermatologie (ZiD)"",""telephone"":""0251-8356558"",""fax"":""[---]*"",""email"":""Athanasios.Tsianakas at ukmuenster.de"",""url"":""[---]*"",""name"":""Mr. Dr. Athanasios Tsianakas""}]"
DRKS00005594,8,10,2017-02-17,"Recruiting complete, follow-up complete",2014-06-30,2016-01-04,58,Actual,18 Years,70 Years,"Both, male and female","[""Additional Inclusion Criteria"",""1. Age: 18 - 70 years, both gender\n2. Patients with generalized chronic pruritus (being actively present for at least 6 weeks prior to screening) AND showing prurigo nodularis of dermatological, systemic or mixed origin\n3. Pruritus was refractory* to a four-week systemic antihistamine therapy (by history, any antihistamine; *no reduction of pruritus by more than two points on VAS)\n4. VAS ≥ 7 (in average during one of the past two days) at Baseline\n5. Signed informed consent\n6. Male patients agree to use a reliable method of birth control during the study.\n7. If the subject is a female of childbearing potential who:\n- has been strictly abstinent 1 month prior to baseline (V2) and agrees to continue for the duration of the clinical trial and for 2 months after end of study\n- and/or agrees to use a highly effective and approved contraceptive method(s) for the duration of the study and for 2 months after end of the study.\nA highly effective method of contraception is defined as:\no combined oral contraceptives (estrogens and progesterone) or implanted or in-jectable contraceptives with a stable dose for at least 1 month prior to Baseline visit AND use of preservative or\no bilateral tubal ligation\no or hormonal intra-uterine device (IUD) inserted at least 1 month prior to Base-line visit AND use of preservative\no or vasectomized partner for at least 3 months prior to baseline\nOr\nFemale of non-childbearing potential, defined as post menopausal (absence of menstrual bleeding for one year without any other medical reasons), hysterectomy or bilateral oophorectomy at Screening and Baseline visit""]","[""Exclusion Criteria"",""1. Patients with\na. chronic pruritus of paraneoplastic, neurogenic, and psychogenic origin\nb. pruritus of dermatologic origin with severe skin inflammation necessitating systemic anti-inflammatory therapy, for example urticaria, bullous pemphigoid, acute generalized flaring up in atopic dermatitis.\nc. localized pruritus (only a single area involved)\n2. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction and/or disease unless currently controlled and stable\n3. Subjects with an underlying known disease, a surgical or medical condition, which in the judgement of the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study or might confound the study assessments (e.g. other dermatological diseases), or might interfere with the subject’s study participation (e.g. planned hospitalization during the study) at Screening and Baseline visits\n4. Subjects with clinically significant abnormal laboratory values according to the Investigator at Screening visit\n5. Current psychosomatic and psychiatric diseases\n6. Current malignant disease and chemotherapy (e.g., hodgkins lymphoma during therapy)\n7. Chemotherapy with etoposide, vinorelbine\n8. Current and past use of topical (washout period 2 weeks) or systemic steroids (washout period 4 weeks) before baseline\n9. Current and past use before baseline of topical and systemic antihistamines such as cetirizine or loratadine (washout period 2 weeks) [remark: During the study the intake of cetirizine as rescue medication is allowed.]\n10. Current and past use before baseline of the following systemic drugs (washout period 4 weeks): ultraviolet A or B light therapy, cyclosporin A and other immunosuppressants, antiepileptics (e.g., midazolam) and anti-cholinergics, antidepressants, pain modulators (gabapentin/pregabalin), opioid receptor agonists or antagonists, anti-anxiety drugs, tranquilizers, hypnotics, antipsychotic drugs (e.g., pimozide)\n11. Current and past use before baseline and planned intake during the study of the following drugs (washout period 4 weeks):\n- drugs strongly inducing CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort (Hypericum perforatum, “Johanniskraut”),\n- ketoconazole, itraconazole, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon, protease inhibitors, irinotecan\n- pimozid, terfenadine, astemizole, cisapride\n- tacrolimus, sirolimus, everolimus, alfentanil, dihydroergotamin, ergotamin, fentanyl, chinidin\n- warfarin, phenprcoumon, midazolam, alprazolam, triazolam, acenocoumarol, tolbutamide\n12. Pregnancy, breast feeding\n13. Subjects currently enrolled in another investigational drug or device study or participated in such a study in the month prior to Baseline visit.\n14. Known hypersensitivity to aprepitant or to any of the excipients, especially sucrose (e.g. patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).""]","[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]","[""- intra-individual difference in verbal rating scale (VRS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively\n- intra-individual difference in VAS at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively.\n- Time course changes in VAS, VRS\n- Time course changes in DLQI, HADS and ItchyQol\n- PBI-P index at visits 4 and 5, and at visits 7 and 8, respectively, compared to Baseline visit 2\n\n""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Münster"",""telephone"":""[---]*"",""fax"":""[---]*"",""email"":""[---]*"",""url"":""http://www.klinikum.uni-muenster.de"",""name"":""""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Kompetenzzentrum chronischer Pruritus (KCP) und Klinik für Hautkrankheiten Universitätsklinikum Münster"",""telephone"":""0251-8356534"",""fax"":""0251-8352559"",""email"":""sonja.staender at uni-muenster.de"",""url"":""[---]*"",""name"":""Ms. Prof. Dr. Sonja Ständer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsklinikum MünsterKlinik für HautkrankheitenZentrale Studienkoordination für innovative Dermatologie (ZiD)"",""telephone"":""0251-8356558"",""fax"":""[---]*"",""email"":""Athanasios.Tsianakas at ukmuenster.de"",""url"":""[---]*"",""name"":""Mr. Dr. Athanasios Tsianakas""}]"
DRKS00005594,9,10,2017-08-15,"Recruiting complete, follow-up complete",2014-06-30,2016-01-04,58,Actual,18 Years,70 Years,"Both, male and female","[""Additional Inclusion Criteria"",""1. Age: 18 - 70 years, both gender\n2. Patients with generalized chronic pruritus (being actively present for at least 6 weeks prior to screening) AND showing prurigo nodularis of dermatological, systemic or mixed origin\n3. Pruritus was refractory* to a four-week systemic antihistamine therapy (by history, any antihistamine; *no reduction of pruritus by more than two points on VAS)\n4. VAS ≥ 7 (in average during one of the past two days) at Baseline\n5. Signed informed consent\n6. Male patients agree to use a reliable method of birth control during the study.\n7. If the subject is a female of childbearing potential who:\n- has been strictly abstinent 1 month prior to baseline (V2) and agrees to continue for the duration of the clinical trial and for 2 months after end of study\n- and/or agrees to use a highly effective and approved contraceptive method(s) for the duration of the study and for 2 months after end of the study.\nA highly effective method of contraception is defined as:\no combined oral contraceptives (estrogens and progesterone) or implanted or in-jectable contraceptives with a stable dose for at least 1 month prior to Baseline visit AND use of preservative or\no bilateral tubal ligation\no or hormonal intra-uterine device (IUD) inserted at least 1 month prior to Base-line visit AND use of preservative\no or vasectomized partner for at least 3 months prior to baseline\nOr\nFemale of non-childbearing potential, defined as post menopausal (absence of menstrual bleeding for one year without any other medical reasons), hysterectomy or bilateral oophorectomy at Screening and Baseline visit""]","[""Exclusion Criteria"",""1. Patients with\na. chronic pruritus of paraneoplastic, neurogenic, and psychogenic origin\nb. pruritus of dermatologic origin with severe skin inflammation necessitating systemic anti-inflammatory therapy, for example urticaria, bullous pemphigoid, acute generalized flaring up in atopic dermatitis.\nc. localized pruritus (only a single area involved)\n2. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction and/or disease unless currently controlled and stable\n3. Subjects with an underlying known disease, a surgical or medical condition, which in the judgement of the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study or might confound the study assessments (e.g. other dermatological diseases), or might interfere with the subject’s study participation (e.g. planned hospitalization during the study) at Screening and Baseline visits\n4. Subjects with clinically significant abnormal laboratory values according to the Investigator at Screening visit\n5. Current psychosomatic and psychiatric diseases\n6. Current malignant disease and chemotherapy (e.g., hodgkins lymphoma during therapy)\n7. Chemotherapy with etoposide, vinorelbine\n8. Current and past use of topical (washout period 2 weeks) or systemic steroids (washout period 4 weeks) before baseline\n9. Current and past use before baseline of topical and systemic antihistamines such as cetirizine or loratadine (washout period 2 weeks) [remark: During the study the intake of cetirizine as rescue medication is allowed.]\n10. Current and past use before baseline of the following systemic drugs (washout period 4 weeks): ultraviolet A or B light therapy, cyclosporin A and other immunosuppressants, antiepileptics (e.g., midazolam) and anti-cholinergics, antidepressants, pain modulators (gabapentin/pregabalin), opioid receptor agonists or antagonists, anti-anxiety drugs, tranquilizers, hypnotics, antipsychotic drugs (e.g., pimozide)\n11. Current and past use before baseline and planned intake during the study of the following drugs (washout period 4 weeks):\n- drugs strongly inducing CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort (Hypericum perforatum, “Johanniskraut”),\n- ketoconazole, itraconazole, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon, protease inhibitors, irinotecan\n- pimozid, terfenadine, astemizole, cisapride\n- tacrolimus, sirolimus, everolimus, alfentanil, dihydroergotamin, ergotamin, fentanyl, chinidin\n- warfarin, phenprcoumon, midazolam, alprazolam, triazolam, acenocoumarol, tolbutamide\n12. Pregnancy, breast feeding\n13. Subjects currently enrolled in another investigational drug or device study or participated in such a study in the month prior to Baseline visit.\n14. Known hypersensitivity to aprepitant or to any of the excipients, especially sucrose (e.g. patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).""]","[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]","[""- intra-individual difference in verbal rating scale (VRS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively\n- intra-individual difference in VAS at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively.\n- Time course changes in VAS, VRS\n- Time course changes in DLQI, HADS and ItchyQol\n- PBI-P index at visits 4 and 5, and at visits 7 and 8, respectively, compared to Baseline visit 2\n\n""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Münster"",""telephone"":""[---]*"",""fax"":""[---]*"",""email"":""[---]*"",""url"":""http://www.klinikum.uni-muenster.de"",""name"":""""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Kompetenzzentrum chronischer Pruritus (KCP) und Klinik für Hautkrankheiten Universitätsklinikum Münster"",""telephone"":""0251-8356534"",""fax"":""0251-8352559"",""email"":""sonja.staender at uni-muenster.de"",""url"":""[---]*"",""name"":""Ms. Prof. Dr. Sonja Ständer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsklinikum MünsterKlinik für HautkrankheitenZentrale Studienkoordination für innovative Dermatologie (ZiD)"",""telephone"":""0251-8356558"",""fax"":""[---]*"",""email"":""Athanasios.Tsianakas at ukmuenster.de"",""url"":""[---]*"",""name"":""Mr. Dr. Athanasios Tsianakas""}]"
DRKS00005594,10,10,2019-03-01,"Recruiting complete, follow-up complete",2014-06-30,2016-01-04,58,Actual,18 Years,70 Years,"Both, male and female","[""Additional Inclusion Criteria"",""1. Age: 18 - 70 years, both gender\n2. Patients with generalized chronic pruritus (being actively present for at least 6 weeks prior to screening) AND showing prurigo nodularis of dermatological, systemic or mixed origin\n3. Pruritus was refractory* to a four-week systemic antihistamine therapy (by history, any antihistamine; *no reduction of pruritus by more than two points on VAS)\n4. VAS ≥ 7 (in average during one of the past two days) at Baseline\n5. Signed informed consent\n6. Male patients agree to use a reliable method of birth control during the study.\n7. If the subject is a female of childbearing potential who:\n- has been strictly abstinent 1 month prior to baseline (V2) and agrees to continue for the duration of the clinical trial and for 2 months after end of study\n- and/or agrees to use a highly effective and approved contraceptive method(s) for the duration of the study and for 2 months after end of the study.\nA highly effective method of contraception is defined as:\no combined oral contraceptives (estrogens and progesterone) or implanted or in-jectable contraceptives with a stable dose for at least 1 month prior to Baseline visit AND use of preservative or\no bilateral tubal ligation\no or hormonal intra-uterine device (IUD) inserted at least 1 month prior to Base-line visit AND use of preservative\no or vasectomized partner for at least 3 months prior to baseline\nOr\nFemale of non-childbearing potential, defined as post menopausal (absence of menstrual bleeding for one year without any other medical reasons), hysterectomy or bilateral oophorectomy at Screening and Baseline visit""]","[""Exclusion Criteria"",""1. Patients with\na. chronic pruritus of paraneoplastic, neurogenic, and psychogenic origin\nb. pruritus of dermatologic origin with severe skin inflammation necessitating systemic anti-inflammatory therapy, for example urticaria, bullous pemphigoid, acute generalized flaring up in atopic dermatitis.\nc. localized pruritus (only a single area involved)\n2. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction and/or disease unless currently controlled and stable\n3. Subjects with an underlying known disease, a surgical or medical condition, which in the judgement of the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study or might confound the study assessments (e.g. other dermatological diseases), or might interfere with the subject’s study participation (e.g. planned hospitalization during the study) at Screening and Baseline visits\n4. Subjects with clinically significant abnormal laboratory values according to the Investigator at Screening visit\n5. Current psychosomatic and psychiatric diseases\n6. Current malignant disease and chemotherapy (e.g., hodgkins lymphoma during therapy)\n7. Chemotherapy with etoposide, vinorelbine\n8. Current and past use of topical (washout period 2 weeks) or systemic steroids (washout period 4 weeks) before baseline\n9. Current and past use before baseline of topical and systemic antihistamines such as cetirizine or loratadine (washout period 2 weeks) [remark: During the study the intake of cetirizine as rescue medication is allowed.]\n10. Current and past use before baseline of the following systemic drugs (washout period 4 weeks): ultraviolet A or B light therapy, cyclosporin A and other immunosuppressants, antiepileptics (e.g., midazolam) and anti-cholinergics, antidepressants, pain modulators (gabapentin/pregabalin), opioid receptor agonists or antagonists, anti-anxiety drugs, tranquilizers, hypnotics, antipsychotic drugs (e.g., pimozide)\n11. Current and past use before baseline and planned intake during the study of the following drugs (washout period 4 weeks):\n- drugs strongly inducing CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort (Hypericum perforatum, “Johanniskraut”),\n- ketoconazole, itraconazole, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon, protease inhibitors, irinotecan\n- pimozid, terfenadine, astemizole, cisapride\n- tacrolimus, sirolimus, everolimus, alfentanil, dihydroergotamin, ergotamin, fentanyl, chinidin\n- warfarin, phenprcoumon, midazolam, alprazolam, triazolam, acenocoumarol, tolbutamide\n12. Pregnancy, breast feeding\n13. Subjects currently enrolled in another investigational drug or device study or participated in such a study in the month prior to Baseline visit.\n14. Known hypersensitivity to aprepitant or to any of the excipients, especially sucrose (e.g. patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).""]","[""intra-individual difference in visual analgo scale (VAS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively""]","[""- intra-individual difference in verbal rating scale (VRS) at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively\n- intra-individual difference in VAS at visit 4 minus Baseline visit 2, and at visit 7 minus “Baseline” visit 5, respectively.\n- Time course changes in VAS, VRS\n- Time course changes in DLQI, HADS and ItchyQol\n- PBI-P index at visits 4 and 5, and at visits 7 and 8, respectively, compared to Baseline visit 2\n\n""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Münster"",""telephone"":""[---]*"",""fax"":""[---]*"",""email"":""[---]*"",""url"":""http://www.klinikum.uni-muenster.de"",""name"":""""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Kompetenzzentrum chronischer Pruritus (KCP) und Klinik für Hautkrankheiten Universitätsklinikum Münster"",""telephone"":""0251-8356534"",""fax"":""0251-8352559"",""email"":""sonja.staender at uni-muenster.de"",""url"":""[---]*"",""name"":""Ms. Prof. Dr. Sonja Ständer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsklinikum MünsterKlinik für HautkrankheitenZentrale Studienkoordination für innovative Dermatologie (ZiD)"",""telephone"":""0251-8356558"",""fax"":""[---]*"",""email"":""Athanasios.Tsianakas at ukmuenster.de"",""url"":""[---]*"",""name"":""Mr. Dr. Athanasios Tsianakas""}]"
DRKS00011665,1,1,2017-01-30,"Recruiting complete, follow-up complete",2015-05-01,2016-10-31,20,Actual,20 Years,50 Years,"Both, male and female","[""Additional Inclusion Criteria"",""Age: 20-50 years; IQ > 85; Diagnosis: ICD-10 F20.0; F25.0; normal or corrected to normal vision (no red-green color blindness)\n""]","[""Exclusion Criteria"",""Epileptic seizures, pregnancy, metallic foreign body implants; pace maker; pregnancy; acute suicidal intent;\n""]","[""Directly after and 24h after stimulation; completion of rating instrument: parametric attentional assessment based on Bundesen’s Theory of Visual Attention (TVA; Bundesen, 1990). (The assessed attentional parameters are: processing speed, visual short-term memory capacity, top-down control)""]","[""Directly after stimulation: completion of Comfort Rating Scale (CRQ) to prove that the application had been running smoothly.""]","[{""label"":""Primary Sponsor"",""affiliation"":""Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität München"",""telephone"":""[---]*"",""fax"":""[---]*"",""email"":""[---]*"",""url"":""[---]*"",""name"":""Mr. PD Dr. Alkomiet Hasan""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Klinik für Psychiatrie und Psychotherapie Klinikum der Universität München"",""telephone"":""0894400 55536"",""fax"":""[---]*"",""email"":""Alkomiet.Hasan at med.uni-muenchen.de"",""url"":""[---]*"",""name"":""Mr. PD Dr. Alkomiet Hasan""},{""label"":""Contact for Public Queries"",""affiliation"":""Institut für Psychologie Ludwig-Maximilians-Universität München"",""telephone"":""089218072537"",""fax"":""[---]*"",""email"":""nadine.goegler at psy.lmu.de"",""url"":""[---]*"",""name"":""Ms. Nadine Gögler""}]"
DRKS00010523,1,1,2016-05-13,"Recruiting complete, follow-up complete",2014-04-04,2014-07-10,20,Actual,18 Years,40 Years,"Both, male and female","[""Additional Inclusion Criteria"",""- voluntary consent\n- male or femal\n- age >18 yeras\n- at least five years of experience in classic and/or modern dance\n- at least five hours training per week""]","[""Exclusion Criteria"",""- acute or chronic trauma and/or disorders of musculoskeletal system\n- scar in the abdomen region\n- pregnancy""]","[""External rotation of the hip, measured by plurimeter before first treatment, after last treatement and one week after last treatment""]","[""Functional turnout, measured by footprint®rotation disc before first treatment, after last treatement and one week after last treatment""]","[{""label"":""Primary Sponsor"",""affiliation"":""Osteopathiepraxis"",""telephone"":""04087090576"",""fax"":""[---]*"",""email"":""praxis at christinelohr.de"",""url"":""[---]*"",""name"":""Ms. BSc Christine Lohr""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Universität Hamburg Fakultät für Psychologie und BewegungswissenschaftInstitut für BewegungswissenschaftArbeitsbereich Sport- und Bewegungsmedizin"",""telephone"":""040428389146"",""fax"":""040428382646"",""email"":""tobias.schmidt at uni-hamburg.de"",""url"":""https://www.bw.uni-hamburg.de/einrichtungen/sport--und-bewegungsmedizin.html"",""name"":""Mr. Dr., BSc, MSc Tobias Schmidt""},{""label"":""Contact for Public Queries"",""affiliation"":""Universität Hamburg Fakultät für Psychologie und BewegungswissenschaftInstitut für BewegungswissenschaftArbeitsbereich Sport- und Bewegungsmedizin"",""telephone"":""040428389146"",""fax"":""040428382646"",""email"":""tobias.schmidt at uni-hamburg.de"",""url"":""https://www.bw.uni-hamburg.de/einrichtungen/sport--und-bewegungsmedizin.html"",""name"":""Mr. Dr., BSc, MSc Tobias Schmidt""}]"
DRKS00005408,1,2,2013-10-30,Recruiting ongoing,2012-04-15,NA,20,Actual,18 Years,no maximum age,"Both, male and female","[""Additional Inclusion Criteria"",""1. Indication for non invasive ventilation\n2. Patients in whom a NAVA-catheter was placed beforehand""]","[""Exclusion Criteria"",""Patients that require invasive mechanical ventilation""]","[""Patient-ventilator interaction (synchrony).\n\nDuring minimum of 20 minute period data from the Ventilator are collected, including:\n- Electrical diaphragmatic activity (Eadi signal)\n- Flow\n- pressure\n- respiratory rate\n\n\nAssessment of patient ventilator interaction is performed offline by analyzing the data after stabilization of NIV.""]","[""Patient comfort is assessed by a visual-analgog scale based rating of comfort. Additionally the patients have to answer the following questions:\n\nDoes the ventilation with the mask make breathing easier?\n\nDo you feel difficulties during expiration?\n\nDoes the ventilator react to fast/slow on?\n\nDo get enough/to much air/support\n\nDo you have the fealing that the mask looses (to much) air?""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsmedizin Göttingen"",""telephone"":""0551399561"",""fax"":""[---]*"",""email"":""omoerer at gwdg.de"",""url"":""[---]*"",""name"":""Mr. Priv. Doz. Dr. med. Onnen Mörer""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Klinik für Anästhesiologie,Universitätsmedizin Göttingen"",""telephone"":""0551399561"",""fax"":""[---]*"",""email"":""omoerer at gwdg.de"",""url"":""[---]*"",""name"":""Mr. Priv. Doz. Dr. med. Onnen Mörer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsmedizin Göttingen"",""telephone"":""0551399561"",""fax"":""[---]*"",""email"":""omoerer at gwdg.de"",""url"":""[---]*"",""name"":""Mr. Priv. Doz. Dr. med. Onnen Mörer""}]"
DRKS00005408,2,2,2019-05-03,"Recruiting complete, follow-up complete",2012-04-15,2016-03-31,26,Actual,18 Years,no maximum age,"Both, male and female","[""Additional Inclusion Criteria"",""1. Indication for non invasive ventilation\n2. Patients in whom a NAVA-catheter was placed beforehand""]","[""Exclusion Criteria"",""Patients that require invasive mechanical ventilation""]","[""Patient-ventilator interaction (synchrony).\n\nDuring minimum of 20 minute period data from the Ventilator are collected, including:\n- Electrical diaphragmatic activity (Eadi signal)\n- Flow\n- pressure\n- respiratory rate\n\n\nAssessment of patient ventilator interaction is performed offline by analyzing the data after stabilization of NIV.""]","[""Patient comfort is assessed by a visual-analgog scale based rating of comfort. Additionally the patients have to answer the following questions:\n\nDoes the ventilation with the mask make breathing easier?\n\nDo you feel difficulties during expiration?\n\nDoes the ventilator react to fast/slow on?\n\nDo get enough/to much air/support\n\nDo you have the fealing that the mask looses (to much) air?""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsmedizin Göttingen"",""telephone"":""0551399561"",""fax"":""[---]*"",""email"":""omoerer at gwdg.de"",""url"":""[---]*"",""name"":""Mr. Priv. Doz. Dr. med. Onnen Mörer""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Klinik für Anästhesiologie,Universitätsmedizin Göttingen"",""telephone"":""0551399561"",""fax"":""[---]*"",""email"":""omoerer at gwdg.de"",""url"":""[---]*"",""name"":""Mr. Priv. Doz. Dr. med. Onnen Mörer""},{""label"":""Contact for Public Queries"",""affiliation"":""Universitätsmedizin Göttingen"",""telephone"":""0551399561"",""fax"":""[---]*"",""email"":""omoerer at gwdg.de"",""url"":""[---]*"",""name"":""Mr. Priv. Doz. Dr. med. Onnen Mörer""}]"
DRKS00003269,1,2,2011-10-04,"Recruiting complete, follow-up complete",2007-01-15,2009-11-16,62,Actual,18 Years,75 Years,"Both, male and female","[""Additional Inclusion Criteria"",""patients with severe keratoconjunctivitis sicca (Dry Eye Severity Level 3, Dry eye severity grading scheme, DEWS 2007); age between 18 and 75 years; education and written consent; severe symptoms; positive staining in fluorescein and rose bengal staining""]","[""Exclusion Criteria"",""pregnancy; breast feeding mothers; other ocular diseases that demand other topical medicatios (anti-glaucoma eye drops); lidanomalies; insufficiency of eyelid closure; ocular surgery within the previous 3 months, especially after refractive surgery or cataract surgery; wearing of contact lenses; systemic or topical application of corticosteroids; uveitis anterior; ocular pemphigoid; Stevens-Johnson-Syndrome; ocular burns; no compliance; underaged patients; written consent not possible""]","[""after 3 months treatment:\n\nstandardized questionnaire for clinical diagnosis features:\n\nLIPCOF; tear break-up time (BUT);\nfluorescein and rose bengal staining; basal secretion of the tear film (Jones test);\nintraocular pressure (IOP);\nOcular Surface Disease Index (OSDI-Score): quality of life questionnaire; profile of cytokines in the tear fluid""]","[""to be omitted""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Erlangen der Friedrich-Alexander Universität Erlangen-Nürnberg"",""telephone"":""09131 8544712"",""fax"":""[---]*"",""email"":""Klinik at augen.imed.uni-erlangen.de"",""url"":""http://www.klinikum.uni-erlangen.de"",""name"":""Ms. Dr.med. Christina Jacobi""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Augenklinik des Universitätsklinikums Erlangen"",""telephone"":""09131 8544712"",""fax"":""09131 8536435"",""email"":""christina.jacobi at uk-erlangen.de"",""url"":""[---]*"",""name"":""Ms. Dr.med. Christina Jacobi""},{""label"":""Contact for Public Queries"",""affiliation"":""Augenklinik des Universitätsklinikums Erlangen"",""telephone"":""09131 8544712"",""fax"":""09131 8536435"",""email"":""christina.jacobi at uk-erlangen.de"",""url"":""[---]*"",""name"":""Ms. Dr.med. Christina Jacobi""}]"
DRKS00003269,2,2,2012-01-11,"Recruiting complete, follow-up complete",2007-01-15,2009-11-16,62,Actual,18 Years,75 Years,"Both, male and female","[""Additional Inclusion Criteria"",""patients with severe keratoconjunctivitis sicca (Dry Eye Severity Level 3, Dry eye severity grading scheme, DEWS 2007); age between 18 and 75 years; education and written consent; severe symptoms; positive staining in fluorescein and rose bengal staining""]","[""Exclusion Criteria"",""pregnancy; breast feeding mothers; other ocular diseases that demand other topical medicatios (anti-glaucoma eye drops); lidanomalies; insufficiency of eyelid closure; ocular surgery within the previous 3 months, especially after refractive surgery or cataract surgery; wearing of contact lenses; systemic or topical application of corticosteroids; uveitis anterior; ocular pemphigoid; Stevens-Johnson-Syndrome; ocular burns; no compliance; underaged patients; written consent not possible""]","[""after 3 months treatment:\n\nstandardized questionnaire for clinical diagnosis features:\n\nLIPCOF; tear break-up time (BUT);\nfluorescein and rose bengal staining; basal secretion of the tear film (Jones test);\nintraocular pressure (IOP);\nOcular Surface Disease Index (OSDI-Score): quality of life questionnaire; profile of cytokines in the tear fluid""]","[""to be omitted""]","[{""label"":""Primary Sponsor"",""affiliation"":""Universitätsklinikum Erlangen der Friedrich-Alexander Universität Erlangen-Nürnberg"",""telephone"":""09131 8544712"",""fax"":""[---]*"",""email"":""Klinik at augen.imed.uni-erlangen.de"",""url"":""http://www.klinikum.uni-erlangen.de"",""name"":""Ms. Dr.med. Christina Jacobi""},{""label"":""Contact for Scientific Queries"",""affiliation"":""Augenklinik des Universitätsklinikums Erlangen"",""telephone"":""09131 8544712"",""fax"":""09131 8536435"",""email"":""christina.jacobi at uk-erlangen.de"",""url"":""[---]*"",""name"":""Ms. Dr.med. Christina Jacobi""},{""label"":""Contact for Public Queries"",""affiliation"":""Augenklinik des Universitätsklinikums Erlangen"",""telephone"":""09131 8544712"",""fax"":""09131 8536435"",""email"":""christina.jacobi at uk-erlangen.de"",""url"":""[---]*"",""name"":""Ms. Dr.med. Christina Jacobi""}]"
